US 11,878,008 B2
Composition for preventing or treating atopic dermatitis
Gyeyoung Choi, Yongin-si (KR); Hyunjin Nam, Yongin-si (KR); Miyoung Park, Yongin-si (KR); Kyoungmi Jung, Yongin-si (KR); Jihae Lee, Yongin-si (KR); Chang Soon Choi, Yongin-si (KR); Youngho Park, Yongin-si (KR); Jong Hwa Roh, Yongin-si (KR); Eunsil Park, Yongin-si (KR); Jaehong Park, Yongin-si (KR); Kwanghyun Shin, Yongin-si (KR); Byoung Young Woo, Yongin-si (KR); Kiwha Lee, Yongin-si (KR); Wonkyung Cho, Yongin-si (KR); and Joonho Choi, Yongin-si (KR)
Filed on Feb. 28, 2020, as Appl. No. 16/805,381.
Application 16/805,381 is a continuation in part of application No. PCT/KR2018/004328, filed on Apr. 13, 2018.
Claims priority of application No. 10-2017-0110669 (KR), filed on Aug. 31, 2017; and application No. 10-2018-0042816 (KR), filed on Apr. 12, 2018.
Prior Publication US 2020/0197379 A1, Jun. 25, 2020
Int. Cl. A61P 17/04 (2006.01); A61K 31/44 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/44 (2013.01) [A61K 9/0014 (2013.01); A61P 17/04 (2018.01)] 16 Claims
1. A method for preventing or treating atopic dermatitis, comprising a step of administering a compound represented by the following Formula 1 of an effective amount to a subject

OG Complex Work Unit Chemistry
wherein the atopic dermatitis is mild or moderate (an Investigator's Global Assessment (IGA) score of 2 to 3), and
wherein the composition improves one or more parameters selected from the following parameters (a) to (c) associated with atopic dermatitis:
(a) improving an IGA grade of 2 for a patient (with mild symptoms) to grade 1 (almost clear symptoms) or 0 (clear symptoms);
(b) improving an IGA grade of 3 for a patient (with moderate symptoms) to grade 1 (almost clear symptoms) or 0 (clear symptoms); and
(c) improving an EASI score and reducing the EASI score by at least 40% or more.